These inhibitor experiments thus confirmed our mutant analysis and demonstrate that the medaka model can be used for future screening of compounds that interfere with Mmp13 activity to potentially prevent osteoporosis or tumor-caused osteolysis. Here, MMP13 is linked to neoplasm.